Year8
/, ) c=CB> c=_c> Sofosbuvir (also translated as & sofosbuvir
Sofosbuvir English namebr trade name) is developed by Gilead for treatment The new drug for chronic hepatitis C was approved by the U.S. Food and Drug Administration to be marketed in the United States on March 21, 2019. This drug is not yet available in China and can only be obtained from foreign hospitals.
The drug is the first to safely and effectively treat certain types of hepatitis C without the need for interferon. Clinical trials have confirmed that the overall sustained virological response rate of this drug combined with pegylated interferon and ribavirin is as high as % against hepatitis C. The R of this drug combined with ribavirin against hepatitis C is %%. This drug is against hepatitis C. The R for combination with ribavirin is %%. It is worth mentioning that the clinical trials of sofosbuvir also included some patients with hepatitis C and cirrhosis, and the efficacy was significant.
The new drug Sofosbuvir for the treatment of hepatitis C has put the controversial US health care reform into another dilemma. Unable to solve health insurance spending problems, some states, including Oregon, are seeking ways to limit the supply of the drug. The expanded Medicaid program proposed by President Obama's health care reform plan has therefore been greatly reduced.
< ) c=>Usage and Dosage
/, ) c=CB> c=_c> Take one tablet per day on an empty stomach or with food (.)
Can be combined with ribavirin or Combined ribavirin + pegylated interferon in the treatment of chronic hepatitis C (). The recommended combination treatment regimen is as follows:
C alone infection
Or/combined infection treatment regimen treatment duration
Gene or type sofosbuvir + pegylated interferon & + ribavir Lin Zhou
Genotype Sofosbuvir + Ribavirin Zhou
Genotype Sofosbuvir + Ribavirin Zhou
Patients with chronic hepatitis C who cannot use interferon may consider using it. Sofosbuvir combined with ribavirin treatment weeks.
Patients with hepatocellular carcinoma awaiting liver transplantation should be treated with sofosbuvir in combination with ribavirin for chronic hepatitis C for 10 weeks or until liver transplantation, whichever occurs first.
Dosing recommendations cannot be made for patients with severe renal impairment or end-stage renal disease.
< ) c=>Overseas new drug therapies
/, ) c=CB> c=_c> In recent years, with the launch of many pharmaceutical companies such as Gilead, Merck, Bristol-Myers Squibb, and AbbVie, The triple regimen and the all-oral interferon-free regimen with this revolutionary drug as its core have gradually replaced the standard treatment regimen. It has greatly improved in terms of cure rate, treatment cycle, side effects, etc. The therapy has now been designated as a breakthrough therapy.
The therapy is a combination of a variety of all-oral drugs. The success rate of interferon-free treatment can reach more than %. It is also effective in the most difficult-to-treat patients with hepatitis C, such as those with advanced fibrosis and cirrhosis, those who are concurrently infected, and those who have received liver transplants. It is worth noting that these new drug combinations require shorter treatment times of less than a week and have fewer side effects that will not dissuade so many people from treatment.
Since all kinds of drugs are currently prescription drugs and have not yet been marketed in China, the only formal channel for domestic patients to purchase them is to go to the countries where they are listed and consult with local doctors to issue corresponding prescriptions and purchase drugs. Currently, the most popular way for patients is to purchase medicines through professional cross-border medical service agencies in the United States, Japan, India and other countries. Among them, the cost of purchasing a course of drugs in the United States/Japan is about ~10,000 US dollars, which is usually difficult for patients to afford. In India, due to its unique drug patent system, regular drugs authorized by the R&D company Gilead can be purchased locally at prices much lower than those in the United States and Japan. The financial burden on patients is small, so going to India to buy specific hepatitis C drugs has become the most popular choice for domestic hepatitis C patients. []
< ) c=>Dosage form
/, ) c=CB> c=_c> Each tablet: .
< ) c=>Contraindications
/, ) c=CB> c=_c> Sofosbuvir combined with pegylated interferon & + ribavirin or alone with ribavirin All contraindications to the use of peginterferon and/or ribavirin also apply to sofosbuvir combination therapy.
Because ribavirin may cause fetal congenital malformations or stillbirth, sofosbuvir combined with pegylated interferon&+ribavirin or sofosbuvir alone combined with ribavirin should be used in pregnant women and Contraindicated in men whose partner is pregnant.
< ) c=>Indications and uses
/, ) c=CB> c=_c> Sofosbuvir is a hepatitis C virus (C) nucleotide analog B polymerase The inhibitor is suitable for use as a combination component in a combination antiviral treatment regimen for the treatment of chronic hepatitis C (HCV) infection.
& Sofosbuvir has been proven to be effective in the treatment of genotyped or genotyped hepatitis C subjects, including hepatocellular carcinoma subjects who meet Milan criteria and are waiting for liver transplantation, as well as C/co-infected subjects.
< ) c=>Warnings and Precautions
/, ) c=CB> c=_c> Pregnancy: Ribavirin may cause fetal congenital malformation or stillbirth, and animal experiments show that interferon can cause abortion. Therefore, female patients and the spouses of male patients taking this drug should avoid pregnancy. Patients must have a negative pregnancy test before starting treatment and must have used at least two non-hormonal methods of contraception and undergo monthly pregnancy tests.
< ) c=>Adverse Reactions
/, ) c=CB> c=_c> The most common known adverse reactions caused by sofosbuvir combined with ribavirin (the incidence rate is equal to or greater than % All grades) are headache and fatigue. The most common known adverse reactions caused by sofosbuvir combined with peginterferon & ribavirin include fatigue, headache, nausea, insomnia and anemia.
Drug Interactions
Potent inducers of intestinal glycoprotein (e.g., rifampicin) may alter the plasma concentrations of sofosbuvir. Please read the complete package insert before use for drug interactions.
Medication for Special Populations
C/Patients with co-infections: The safety and effectiveness of this drug have been confirmed by research.
Hepatocellular carcinoma patients awaiting liver transplantation: The safety and effectiveness of this drug have been confirmed by studies.
This drug has been launched in the UK and the US but has not yet been launched in China. Domestic customers who want to purchase this drug can seek help through large US chain pharmacies such as [ ].
Similar products on the site
Jiangsu TV station city channe
Negotiable
Handle Beijing company registr
Negotiable
What is the minimum registered
Negotiable
Wholesale ice crystal painting
￥15000.00/瓶
Hushan Professional Lighting a
Negotiable
Negotiable
How about opening a car beauty
Negotiable
A new choice for Nanyang entre
Negotiable
Direct chartered car from Yiwu
￥1.00/瓶
￥1.00/瓶
"Daclatasvir price in India Daclatasvir manufacturer 13621079267"Related Products
- Related categories
- Related Information
- SEO communication Professional agency Hubei formwork and s Professional agency for Wuhan building d Professional agency for Hubei mechanical Professional agency for professional con Professional agency for general contract Professional agency for general contract Professional agency for general contract The project application report was prepa Goodbye flowers bloom, with such a set o Private chauffeur rental Shanghai pharmaceutical cold chain, Shan For cold chain round-trip logistics dedi Refrigerated transportation, cold chain If you are looking for Shanghai Refriger
The information/pictures/parameters, etc. displayed on this webpage about【Daclatasvir price in India Daclatasvir manufacturer 13621079267】are provided by member【Beijing Xiangrui Import and Trade Technology Co., Ltd. 】，By Titker Trade Network members 【Beijing Xiangrui Import and Trade Technology Co., Ltd. 】is solely responsible for the authenticity, accuracy and legality of the information/pictures/parameters, etc.，Titker Trade Network only provides display services. For your safety, please choose Titker Trade Network for online trading, otherwise Titker Trade Network will not bear any responsibility for this.
If your legitimate rights and interests have been infringed, please contact Titker Trade Network customer service as soon as possible. We will serve you wholeheartedly. Thank you for your attention and support to Titker Trade Network!
WhatsApp
